Table 6.

Adverse Events by Treatment Group

Adverse Event	No.			P Valuea
	Voriconazole	Natamycin	Total
Serious
Corneal perforation	15	10	25	.31
TPK	29	13	42	.01
Corneal perforation and/or TPK	34	18	52	.02
Endophthalmitis	2	0	2	.50
Other serious ocular event thought to be related to study drug	0	0	0	NA
Death	1	1	2	>.99
Nonelective surgery, hospitalization, or loss of function	0	0	0	NA
Myocardial infarction or stroke	1	0	1	>.99
Nonserious
Local allergic reaction	0	0	0	NA
>2-mm increase in hypopyon	12	5	17	.09
>50% Increase in infiltrate size	13	5	18	.06
Intraocular pressure ≥35 mm Hg for 1 wk despite therapy	0	0	0	NA
Progressive corneal thinning to ≤50% of thickness at enrollment	2	0	2	.25
Other nonserious	3	3	6	>.99

Abbreviations: NA, not applicable; TPK, therapeutic penetrating keratoplasty.

^aFisher exact test.